Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 1.3.2023Zentiva, k.s. (ZNT-1)9823DKapidin 20 mg (tbl flm 30x20 mg (blis.Al/PVC/PVDC))7.11.2022U
 1.3.2023Berlin-Chemie AG (BCE)46960L-Thyroxin 150 Berlin-Chemie (tbl 100)3.3.2023O
 1.3.2023Berlin-Chemie AG (BCE)46957L-Thyroxin 125 Berlin-Chemie (tbl 100)3.3.2023O
 1.3.2023Berlin-Chemie AG (BCE)15394L-Thyroxin 100 Berlin-Chemie (tbl 100x100 µg (blis.Al/Al))3.3.2023O
 1.3.2023MIP Pharma GmbH (MIP)4741BVancomycin MIP 500 mg (plv ifo 5x500 mg (liek.inj.skl.))1.3.2023O
 1.3.2023MIP Pharma GmbH (MIP)4743BVancomycin MIP 1 000 mg (plv ifo 5x1000 mg (liek.inj.skl.))1.3.2023O
 1.3.2023Teva B.V. (TEV-NL-4)51633Valsartan Teva 80 mg (tbl flm 28x80 mg (blis.PVC/PE/PVDC/Al))25.4.2023R
 1.3.2023ratiopharm GmbH (RAT)33453Bisoprolol-ratiopharm 10 mg (tbl 30x10 mg (blis.Al/PVC/PVDC))28.2.2023O
 1.3.2023ratiopharm GmbH (RAT)36306Fentanyl ratiopharm 50 µg/h (emp tdm 5x50 µg/1 h (vre.papier/PE/Al/surlyn))27.2.2023O
 28.2.2023Novartis Slovakia s.r.o. (NVL-2)40587TOBRADEX (ung oph 1x3,5 g (tuba Al))3.3.2023R
 28.2.2023Novartis Slovakia s.r.o. (NVL-2)95041Sandimmun 50 mg/ml (con inf 10x1 ml/50 mg (amp.skl.))28.2.2023O
 28.2.2023B.Braun Melsungen AG (BME)1350CNutriflex Omega special bez elektrolytov (emu inf 5x1250 ml (vak infúzny viackomorový))28.2.2023O
 28.2.2023GlaxoSmithKline Biologicals S.A. (GAG)28654Priorix (plv isl 10x0,5 ml+10x0,5 ml solv. (liek.inj.skl.+striek.inj.skl.napl.s 2 oddel.ihlami))17.2.2023O
 28.2.2023GlaxoSmithKline Biologicals S.A. (GAG)01399Infanrix Polio (sus iru 10x0,5 ml (striek.inj.napl.skl.+10 ihiel))27.2.2023O
 28.2.2023P&G Health Germany GmbH (PGT)92927Nasivin Soft 0,01 % (int nao 1x5 ml (fľ.PE))16.1.2023R

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To